Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
December 2024—Siemens Healthineers now offers Atellica Integrated Automation on the Atellica CI analyzer, to consolidate 25 tasks, including sample management and decapping and sealing functionality, typically handled manually by clinical laboratory staff. With Atellica Integrated Automation, one technologist can manage calibration and QC, daily sorting, and archiving processes in minutes, according to a company press statement.
December 2024—Biofidelity announced the launch of its Aspyre Clinical Test for Lung for liquid biopsy samples. Using either a tissue or blood sample, the test detects somatic mutations from DNA and gene fusions from RNA within two days. “Currently, patients who are fortunate enough to receive molecular testing often have to wait weeks for the results, with many tests failing altogether,” Barnaby Balmforth, PhD, Biofidelity cofounder and CEO, said in a press statement. “Aspyre Clinical Test for Lung’s unmatched next-day turnaround time coupled with its best-in-class performance from tissue and blood and proven performance with challenging samples makes simplified genomic profiling via Aspyre a game-changer for patients and the clinicians treating them.”
December 2024—Qiagen has called for a sharper focus on testing strategies to stop new cases of tuberculosis from erupting and spreading in the United States. The U.S. has maintained one of the lowest TB rates in the world, but case counts across all age groups have risen every year since 2020, including a 16 percent increase in cases from 8,320 in 2022 to 9,615 in 2023 (Williams PM, et al. MMWR Morb Mortal Wkly Rep. 2024;73[12]:265–270). The American Academy of Pediatrics updated its TB screening guidelines this year to encourage use of blood-based testing for children of all ages, including from birth to two years old.
December 2024—Foundation Medicine announced it has received approval from the FDA for FoundationOne Liquid CDx to be used as a companion diagnostic for tepotinib (Tepmetko, EMD Serono). Tepmetko received accelerated approval from the FDA in February 2021 and traditional approval in February 2024 for the treatment of adult patients with metastatic non-small cell lung cancer harboring mesenchymal-epithelial transition exon 14 skipping alterations.
December 2024—Illumina announced it will release TruSight Oncology 500 v2, a new version of its flagship cancer research assay to enable comprehensive genomic profiling. The assay is under development; a worldwide release is planned for midyear 2025. TSO 500 v2 assesses hundreds of genes across all variant classes, as well as immuno-oncology biomarkers, in a single assay from one sample. Features of the new version include a faster turnaround time and reduced hands-on time; sensitive variant calling and improved coverage of difficult genomic regions; and new kit configurations with 50 percent less packaging, 70 percent fewer tubes, and improved usability.
December 2024—Verichem Laboratories announced that it is now offering clinical reference materials intended for calibration and calibration verification procedures for total cholesterol, high-density lipoprotein, and low-density lipoprotein. The liquid-stable, ready-to-use Matrix Plus Total Cholesterol Reference kit, Matrix Plus Total Cholesterol Reference kit level F, and HDL Cholesterol Verifier kit feature universal compatibility with a variety of automated clinical chemistry systems. The serum-like formulation contains a blend of highly purified human source material and bovine biologicals in saline.
December 2025—Revvity has launched its in vitro diagnostic EuroRealTime APOE assay in European countries that accept the CE mark. The test aims to help assess a patient’s risk for side effects prior to the start of an anti-amyloid therapy for Alzheimer’s disease. The real-time APOE PCR test allows simultaneous detection of the three most frequent APOE forms—E2, E3, and E4. Assay processing can be automated to scalable degrees on Revvity instruments, including the Euroimmun PreNAT II and Chemagic 360 platforms. Results are evaluated, documented, and archived using EuroRealTime analysis software.
December 2024—Roche announced FDA approval of a label expansion into biliary tract cancer for the Pathway anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test, a companion diagnostic to aid in the assessment of HER2-positive status to identify patients with biliary tract cancer who are eligible for treatment with zanidatamab-hrii (Ziihera, Jazz Pharmaceuticals). Ziihera is an FDA-approved treatment for adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer. The Pathway HER2 (4B5) test is used in combination with the Ventana BenchMark slide staining instrument.
December 2024—Hardy Diagnostics announced it has entered into an exclusive partnership with Swedish-based company Gradientech to distribute Gradientech’s QuickMIC system in the United States and Canada. QuickMIC is an ultra-rapid antimicrobial susceptibility testing system designed to provide critical results for sepsis patients. The system and its gram-negative panel are CE marked. QuickMIC received FDA breakthrough device designation last year.
November 2024—Novartis announced FDA approval of Kisqali (ribociclib) in combination with an aromatase inhibitor for the adjuvant treatment of people with HR+/HER2- stage II and III early breast cancer at high risk of recurrence, including those with node-negative disease.
